Genetic testing for PACS2 was first reported in 2018 by Olson et al. [7], who published the first study describing 14 unrelated individuals affected by a molecular spectrum of PACS2 mutations that resulted in intellectual disabilities with paroxysmal epileptic manifestations. The gene discussed is PACS2; the disease is Intellectual disability.